Lower U.S. tariffs on South Korean imports set to benefit Hyundai and GM.

Sutro Biopharma has dosed the first cohort of patients in its Phase 1 trial of Stro-004, a single homogeneous ADC directed against tissue factor for the treatment of solid tumors. The trial is part of Sutro's efforts to develop targeted cancer therapies using its integrated cell-free protein synthesis platform, XpressCF, and site-specific conjugation platform, XpressCF+.